international medical research pty ltd

International Medical Research Pty. Ltd.

• Australian Private Company

International Medical Research Pty. Ltd. is a Western Australia based Australian Private Company registered 10th May 1996. It is registered for GST.

Other Entity Names

Reference ids, other details, contact australia check.

• Log in/Sign up

INTERNATIONAL MEDICAL RESEARCH PTY. LTD.

• SOUTH PERTH
• Western Australia

Recent filings for INTERNATIONAL MEDICAL RESEARCH PTY. LTD.

see all filings

Latest Events

Corporate grouping user contributed, identifiers.

Problem/question about this data? Click here

For access please Log in / Sign up

We have detected that JavaScript is currently disabled in your web browser. ib.com.au relies on Javascript to deliver its content to you - Please enable Javascript in order to continue.

Note: if you're using internet explorer this may be due to internet explorer enhanced security settings. please add informationbrokers.com.au to your trusted sites - instructions can be found here..

• PAY INVOICE

View Cart    Checkout

• ALL PRODUCTS
• Free Company Reports

- Free Company Report

Important notice:.

Information Brokers Pty Ltd is not affiliated with any of the companies appearing on this site , and does not hold their contact details (Including Phone Numbers). We are an accredited credit reporting agency that provides risk assessments of companies and their directors.

A credit report provides an indicator of business stability through its organisation overview, director details, corporate structure and debt and payment habits. The report contains detailed information about ( ACN - ) and its directors including a credit rating score to quickly establish if you want to extend credit to the company.

A free alert system is provided when or its officers submit documents to ASIC or the PPSR. This alert is delivered to you via email. If you choose you can order a new credit report by using the link provided within the alert.

An overview of the company name(s), address(es) and type(s) over time, detailing all historical changes where applicable.

A list of directors and officeholders, past and present, and details of their tenures over time. Includes personal details (dates of birth, addresses) and any director court orders and details where applicable.

A list and summary of charges lodged against the company in ASIC, and their status (satisfied, unresolved etc).

Documents attached to the company in ASIC, including company amendments, court orders, and external administration and/or appointment of controller where applicable.

The company's credit score out 100 with a breakdown of charges, annual returns, share capital and other relevant details.

A free alert system is provided when or it's officers submit documents to ASIC or the PPSR direct to your inbox.

Please Note: The information presented on this page is historical in nature meaning the status and other information of this company and any associated business name(s) may not be current. Only by ordering a Company Credit Report or Company Extract can you obtain the current company information on .

TODAY'S IDEAS TOMORROW'S SOLUTIONS

The Centre for Innovative Medical Research Pty Ltd (CIMR) was established to accelerate national and international collaboration for ideation, research, development, and commercialization of medical scientific breakthroughs for the benefit of humankind.

While science and technology have never been more innovative and successful, there are still numerous key medical and environmental health problems that remain unsolved.

​Impediments to solving these problems arise from:

Highly bureaucratic and lengthy research funding processes

Difficulty funding truly creative ideas outside of the accepted scientific dogma

Outdated ‘fear of failure’ culture

Divide between academia and industry

Pressure for young scientists to compete for few tenured positions - leading to research solely geared to publishing numerous papers

Long ‘time to market’ process that can often lead to the loss of golden opportunities

Current academic reward system penalizes industry collaboration, with the focus solely being on publications and citations.

Limited support of researchers by many Australian universities which are reducing opportunities for translation and increasing researchers’ teaching loads

CIMR was founded to address many of these challenges via:

Commercialisation.

INTERNATIONAL MEDICAL RESEARCH PTY. LTD.

Credit report.

• Shareholders
• Credit Score
• Payment Predictor
• Historical Timeline

CreditorWatch - Helping you get paid

Creditorwatch is an affordable and easy-to-use credit management solution providing you:.

• Unlimited access to over 10,230,000 Credit Reports
• Customer Monitoring & Alerts
• Credit Score & Recommendations
• Debt Collection Tools

Reports Provided by

Summary Information

Asic data - directors / addresses / shareholdings, asic data*.

Search for information on a company, and identify directors with a history of running failed entities.

• Director Details - Addresses & Date of Birth*
• Cross Directorships*
• Shareholders and Share Structure*
• Company Addresses*
• Company Status*

Adverse Risk Data

Recognise high risk indicators that could impact a company's ability to pay your invoices.

• Payment defaults
• Court actions
• Insolvency notices
• Mercantile (debt collection) enquiries
• Critical ASIC documents

Safeguard trading decisions using statistically based credit scores to determine the level of risk associated with an entity.

• Instant credit risk rating
• Suggested trading recommendation
• 12-month historical score

See how individual companies pay other suppliers to predict how they will pay you

• 12-month historical trend
• Payment insights
• Credit exposure
• Overdue amounts

Monitoring and Alerts

Automated customer risk monitoring will alert you when a customer's circumstances changes. Alerts cover adverse changes such as payment defaults, court actions, director changes, financial distress and administrator appointments.

• Respond to changes quickly
• Add and remove customers as required
• Receive alerts as they happen, 24/7

Identify positive and negative behavioural trends by reviewing an entity's historical timeline, detailing events from the registration date to present day.

Business Names

A registered business name is a trading name under which a person or entity carries on business or trades. A business name extract enables you to identify the entity carrying on a business under a business name and it's contact details.

REPORT NAVIGATION

• ABR Information
• ASIC Information
• Court Actions
• Payment Defaults
• Insolvency Notices
• Mercantile Enquiries
• Directors & Officeholders
• Shareholdings
• Documents Lodged
• Alerts 24/7

See how easy credit checks are with CreditorWatch

In 4 simple steps see how CreditorWatch can help you perform due diligence.

How well do you know your customers?

Trade with confidence and reduce credit risk by reviewing your customers and prospects today.

• HOW IT WORKS

Headquartered in Sofia, we promote a high level of ethical and professional standards. Our experience makes us a preferred partner for providing the best-in-class solutions. We have built strong partnerships with pharmaceutical and biotech companies and we have worked with many of the leading healthcare professionals in Bulgaria. Thus we can successfully act as a connection between patients and pharma industry. We combine our belief in quality and customer care with a can – do spirit. IMR’s team has a deep knowledge in science of cancer, immunology and infectious diseases.

Personalized medicine

IMR is a company with interests and activities focused on innovations in the field of personalized medicine and biotechnology.

Human Tissue and Biofluids Procurement

We are professionals in the logistics of human tissues and biofluids and follow professional and ethical norms.

Scientific Projects

Our team has vast expertise in a wide range of therapeutic areas. We have a proven experience in medical projects writing and editing.

Validation Studies

IMR can provide patients’ recruitment for validation studies mainly but not exclusively in the area of oncology and infection diseases.

Clinical Research Services

IMR provides CRO services to support your research initiative. Our services are following ICH, GCP and regulatory guidelines.

HTA Services

IMR Team experience and knowledge makes us the right partner for your HTA projects and market access.

Quality Policy

At IMR we are committed to maintain the professional quality of our work and the high level of service we provide to our clients. We strictly follow ICH and own a QMS in compliance with the GCP standard. It’s a must for us to have a clear vision for our clients’ needs and to meet them throughout any project or duration of the services provided. In order to achieve this we are guided by a set of standard operating procedures, international guidelines, and proven good practices.

• Financial Reports
• Presentations
• Market Announcements
• Annual Meetings
• Shareholder Information
• Corporate Governance
• Our History
• Our Operations
• Leadership Team
• Board of Directors
• Partnerships

A heritage of progression

A heritage of innovation, a heritage of leadership.

Home > About > Our History

50 years of landmark achievements born of vision, ambition and dedication.

Medical Developments International Pty Ltd, founded by Dr David Komesaroff

Invented the Komesaroff Oxy Resuscitator

Designed the ‘Green Whistle’

MDI Ltd listed on ASX

Penthrox® trademarked

Registration of MDI’s first spacer

MDI purchases the Breath-A-Tech® range

MDI global manufacturing facility in Scoresby is opened

Penthrox® registered in Europe

Collectively our acute pain and respiratory products are registered in over 40 countries

MAT-AU-BAT-WB-0013

We are passionate about helping transform patients’ lives through the development and distribution of innovative medical devices.

Welcome to Medical Developments International. In order to provide a more relevant experience for you, we use cookies to enable some website functionality. Cookies help us to improve the user’s experience, to protect your information, as well as to develop aggregated statistics on the data collected. For more information, please review our Cookies Policy and Privacy Statement .

Thank you for your enquiry.

We will be back in touch shortly.

Receive investor news

Great to have you onboard, and we look forward to keeping you updated. To unsubscribe, please use the Contact page .

You are now leaving the Medical Developments International website

We are not responsible for the content, views, or privacy policies of this external site.

Don't have an account? Register here

Queensland Health Research Excellence Showcase 2024

Partnership and translation.

The inaugural Queensland Health Research Excellence Showcase 2024 will be held on Friday 3 May 2024, hosted by the Office of Research and Innovation.

Recognising research achievements across Queensland Health, the theme, Partnership and Translation, focuses on celebrating and highlighting the pivotal role that partnerships, research translation and commercialisation play in advancing medical research, workforce development and healthcare.

Join Queensland Health's Director-General, Michael Walsh, as he announces the winners of the research awards, including the Research Translation Excellence Award, Industry Partnership Excellence Award, People's Choice Awards, and Translation and Commercialisation Pitching Awards.

Program for 3 May 2024

Professor Ian Frazer is a clinician scientist, trained as a clinical immunologist in Scotland. As an Emeritus Professor at the University of Queensland, he led a research group working at TRI in Brisbane on the immunobiology of epithelial cancers. He is recognised as co-inventor of the technology enabling the HPV vaccines, currently used worldwide to help prevent cervical cancer.

He heads a biotechnology company, Jingang Medicine (Aus) Pty Ltd, working on new vaccine technologies, and is a board member of Microba Pty Ltd and of some not-for-profit organisations. He was the inaugural president of the Australian Academy of Health and Medical Sciences, and co-chairs the Advisory Board of the Medical Research Future Fund.

He was recognised as Australian of the Year in 2006; recipient of the Prime Minister’s Prize for Science, and the Balzan Prize in 2008, and was elected Fellow of the Royal Society of London in 2012. He was appointed Companion of the Order of Australia in the Queen’s Birthday Honours list in 2013.

Angela is a Queensland-born registered nurse and midwife with an interest in life course epidemiology – specifically,  pre- and gestational- environmental exposures and their association with foetal, childhood, adolescence and adult health and disease risk. Angela spent many years working in the Northern Territory and consequently established a research partnership with the Ngaanyatjarra Pitjantjatjara Yankunytjatjara (NPY) Women’s Council and Northern Territory Health Service to oversee her Doctoral studies through The University of Queensland.

Her PhD examined and compared with smoking, the impact of chewing Australian wild tobacco plants (pituri), on Indigenous maternal and perinatal outcomes. Her findings provided new information for the over 90 million women globally who chew tobacco, and to the health professionals and researchers who work with these often disadvantaged and marginalised groups of women.  The findings also form the basis for Angela’s current study which extends into regional and rural Indigenous populations. Angela was awarded a Centaur Fellowship in 2013 and has previously been awarded a Queensland Health Research Fellowship (2012-2017- $525,000) and is a current recipient of a Queensland Health Clinical Research Fellowship (2020-2024 - $300,000). Angela is the Director of Research at the Wide Bay Hospital and Health Service.

Professor Jonathan Golledge holds a conjoint position between the College of Medicine and Dentistry at James Cook University (JCU) and The Queensland Health facility at Townsville University Hospital, where he works as a vascular surgeon. In addition to providing a high quality clinical service, his principal aspiration is to improve management of peripheral vascular diseases. The research impact of this is evidenced by external grant support from the NIH, NHMRC, Queensland Government, MRFF, NHF and other bodies. Of note in 2010 Professor Golledge led a successful bid to establish a NHMRC funded centre of research excellence for Peripheral Vascular Disease.

Professor Golledge is Head of the Queensland Research Centre for Peripheral Vascular Disease and its pre-clinical arm The Vascular Biology Unit at the College of Medicine and Dentistry, JCU and Townsville University Hospital. Professor Golledge joined JCU in 2002 and established the Vascular Biology Unit with the aim of carrying out research intended to be translated into improved management of abdominal aortic aneurysm and other peripheral vascular conditions. We continue to seek high quality students and researchers to join our group. Trained as a vascular specialist, Professor Golledge took 2 years out of specialist training to obtain experience in research techniques as part of a Cambridge MChir (Doctoral equivalent), UK. His research commitment is illustrated by a large number of presentations at International and National meetings and publications in peer-reviewed journals, including a large number in top specialised journals.

Professor John F Fraser MB ChB PhD FRCP(Glas) FFARCSI FCICM FELSO is Founder/Director of the Critical Care Research Group at The Prince Charles Hospital, Metro North Hospital and Health Service, Director of Intensive Care at St Andrew’s War Memorial Hospital, and Immediate Past President of the Asia Pacific Extracorporeal Life Support Organisation (APELSO).

Consisting of a world-leading collaborative of clinicians, engineers and scientists, the Critical Care Research Group (CCRG) is Australia’s largest multidisciplinary medical research groups. It boasts 8 purpose-built labs including the largest preclinical ICU in the southern hemisphere with connections across all major international cardiothoracic hospitals.

He and the team completed a five-year body of work to assess machine perfusion in optimising conditioning of donor hearts. This pre-clinical work led to an international clinical trial that has revolutionised the practice of heart transplantation by allowing hearts to remain outside the body for up to 9 hours. This practice has been adopted worldwide.

Professor Fraser developed an " inhalable epipen " equivalent for treatment of anaphylaxis, co-founded  the BiVACOR total artificial heart company with Dr Daniel Timms, the device’s inventor, and in 2020 established the COVID-19 Critical Care Consortium with CCRG colleagues A/Prof Gianluigi Li Bassi and Dr Jacky Suen. The Consortium has created what is now widely regarded as the world’s largest and most in-depth COVID-19 ICU database spanning >460 hospitals in 64 countries resulting on over 35 manuscripts and treatment changing discoveries.

John has five professorships, over 650 publications many in peer-reviewed journals, has received more than AUD 90 million in competitive grants, and co-wrote and edited the most comprehensive textbook on mechanical circulatory support.

Prof Julie White, as the Executive Director, Office of Research and Innovation in the Clinical Planning and Service Strategy Division of Queensland Health, is responsible for matching Queensland research capabilities – in hospitals, universities, research institutes and businesses – with partners, and translating research into improved health outcomes for patients.

Julie leads the strategic direction of medical research, including ethics and governance for clinical trials, at all Queensland public hospitals.  She oversees the Australian Teletrial Program which is making clinical trials more accessible for patients in remote regions of Australia. She also leads the Department of Health’s international business development activities.

Prior to joining Queensland Health, Julie was the Director of Health, Research and Enterprise Development at Deakin University.  She has held Chief Executive roles at companies and research centres in Australia and Europe.

Professor Clair Sullivan is an internationally-recognised leading practising and academic clinical informatician who helps drive digital health transformation in Queensland and globally.

Clair is the Director of the new Queensland Digital Health Centre within the Centre for Health Research at The University of Queensland.

A specialist endocrinologist, Clair graduated with Honours in Medicine from The University of Queensland and earned a Research Doctorate in Medicine from the University of Leeds. In 2014, Clair began a parallel career in the emerging field of digital health and has held significant leadership roles in digital health practice and governance across government and academia. Her work is regularly translated into practice and informs policy in Australia and globally.

Clair was appointed the inaugural Professor of Digital Associate Professor of Medicine in Clinical Informatics at UQ and is an Adjunct Professor at the Faculty of Health, Queensland University of Technology, and an Adjunct Professor, School of Health and Biomedical Sciences at Royal Melbourne Institute of Technology.

She is a fellow of the Royal Australasian College of Physicians, the Australian College of Health Informatics and the Australasian Institute of Digital Health.

Clair serves on several national advisory boards for digital health. She is the recipient of several awards including the 2021 Premier's Award for Excellence for her team's work on the digital response to COVID-19 and the 2022 Telstra Brilliant Connected Women in Digital Health Award.

She has generated over $30M in grant funding and has deep collaborations with government and industry. She is ranked in the top 1 per cent of Medical Informatics researchers globally.

Dr Iris Depaz, PhD EMBA GCHEd is the Head of Medical, Vaccines, Sanofi ANZ & South Korea. Iris obtained her PhD in Biomedical Sciences at the University of Queensland, Australia. Following this she conducted post-doctoral research in the area of neuronal drug metabolism and alcohol dependency. She received her eMBA with Honors from the IMD Business School in Lausanne Switzerland in December 2020.

She first moved into industry in 2007 working as a Scientific Advisor and Medical Science Liaison (MSL) in Diabetes for GlaxoSmithKline (GSK) Australia in Diabetes. In 2009 she moved into Vaccines as an MSL, and during her time in Australia held increasing senior roles as an MSL manager and Senior Medical Advisor. Iris moved in 2012 to the GSK Global Vaccines Head Office in Belgium, where she was first a Global Medical Affairs Senior Manager then Global Medical Access Lead for the MMRV vaccine franchise.

Iris joined Sanofi in 2015 as the Global Head of the MSL Centre for Excellence based in Lyon France. During this time Iris also served as the Chair of the Sanofi Global Cross-GBU MSL Task Force. In 2018, Iris launched the Medical Effectiveness Department where she led the establishment of the Medical Capabilities, Insights, Content Development and Medical Education platforms.

Her current role leverages her long experience in vaccines as well as her country experience in Australia/New Zealand, to enhance and strengthen local external scientific interactions with stakeholders.

Melissa has more than 15 years of experience in the life sciences sector, with expertise in multiple therapeutic areas, medical research, translation, strategy, and commercialisation.

Melissa holds a PhD in Cardiovascular Physiology from Monash University/Baker Institute, has completed a Postdoc from Johns Hopkins Medicine in Baltimore and made significant contributions to various biotech start-up companies.

She was part of the founding team for Cardiac Dimensions Inc, Osprey and V-Kardia, and has had roles in both Research & Development and Clinical Operations for a number of biomedical startups.

Noel Chambers is currently Chief Executive Officer of the National Foundation for Medical Research and Innovation. He has a PhD in pharmacology/medicinal chemistry from the University of Sydney. His work experience includes positions in research, research translation, commercialisation, start-up companies, biotechnology and philanthropy.

In the early 90s his patented discoveries in Type II diabetes led to a commercial partnership where he led a team of researchers at the University of Sydney and for which he was presented the Royal Australian Chemical Institute’s Biota Award for Medicinal Chemistry. Noel then moved into industry where he held senior management positions in research and business development before becoming the CEO of a number of listed (ASX) and unlisted biotechnology/health related companies. In 2009, Noel’s attention turned to philanthropy where he led the establishment of Research Australia’s successful philanthropy program as the Director of Philanthropy. He was a member of the Federal Government’s Advisory Council for Intellectual Property (ACIP) from 2009-2014, advising the Federal Minister for Innovation, Industry, Science and Research and was Chair of the ACIP review into collaborations between Publicly Funded Research Organisations and Industry.

Dr Mark Ashton is the  Director, Griffith Enterprise at Griffith University. He has over 25 years’ experience in numerous roles in the biotechnology, technology transfer and pharmaceutical industries. Mark joined Griffith University as the Director, Griffith Enterprise in April 2023 to lead their commercialisation activities. Prior to this, he spent 12 years with UniQuest Pty Ltd, the commercialisation company of The University of Queensland and led the commercialisation team as the Executive Director, Commercialisation.

Prior to joining UniQuest, Mark was the Executive Vice President, Business Development and a member of the Executive Management Committee of Evotec AG, a publicly listed, European-based Biotechnology company. At Evotec he led the business development team and also worked in other senior management roles during his 15 years. During his career Mark has led numerous strategic collaborations with global biotech and pharmaceutical companies, enabling mutually beneficial partnerships and has raised investment for start-ups and licensed technologies to international and domestic companies. He also has experience as a Director on the Board of a number of private companies in Australia.

Ballet for Brain Injury - Queensland Ballet

Queensland Health is proud to support the newly launched Van Norton Li Community Health Institute for their clinically designed dance rehabilitation, mobility and strength classes for key groups throughout the state.

The Institute will showcase this through a demonstration of their weekly Ballet for Brain Injury program, along with the Queensland Ballet Academy dancers performing a section from ‘Tchaikovsky Suite’.

Dance has been shown to help people surviving brain injury to re-inhabit their bodies and cope with emotional, cognitive and physical impairments, as well as opportunities for social connection.

This demonstration will feature community participants and Teaching Artists, to illustrate research in practice through dance, movement, music and creativity on stage.

Last updated: 22 April 2024